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Purpose: With the use of 12 months of follow-up data, this study was conducted to eval-
uate the efficacy of photoselective vaporization of the prostate (PVP) with the 120 W 
Greenlight high performance system (HPS) laser for the treatment of symptomatic be-
nign prostatic hyperplasia.
Materials and Methods: Data were collected from 104 patients who were diagnosed with 
benign prostatic hyperplasia and who underwent PVP with the 120 W Greenlight HPS 
Laser. Postoperative parameters, including International Prostate Symptom Score 
(IPSS), quality of life (QoL) score, maximum urinary flow rate (Qmax), and postvoid 
residual volume (PVR), were assessed and compared with preoperative baseline values. 
Results: The mean age of the patients was 71.1±7.7. The baseline mean prostate-specif-
ic antigen level was 3.8±2.7 ng/ml, the mean prostate size was 43.9±20.6 g, the mean 
preoperative IPSS was 18.4±8.5, the mean QoL score was 4.1±1.0, the mean Qmax was 
9.9±5.5 ml/sec, and the mean PVR was 89.6±207.1 ml. During surgery, the mean oper-
ation time was 21.8±11.3 minutes, the mean lasing time was 16.9±10.5 minutes, and 
the mean total applied energy was 170,068±63,181 J. At 1 month, significant improve-
ments were observed in total IPSS (11.5±6.7, p＜0.05), voiding symptom score (6.1±5.4,
p＜0.05), and QoL score (2.2±1.5, p＜0.05); however, there were no significant improve-
ments in storage symptom score (4.8±3.8, p=0.06), Qmax (12.6±10.2, p=0.06), and PVR 
(40.1±30.5, p=0.41). However, 3 months after surgery, all postoperative follow-up pa-
rameters showed significant improvements, and the 6- and 12-month data showed sus-
tained improvement of postoperative follow-up parameters. 
Conclusions: Significant improvements were observed in subjective and objective void-
ing parameters, which were evident at 3 months after PVP and were sustained through-
out a period of 12 months after PVP. 
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INTRODUCTION
The prevalence of benign prostatic hyperplasia (BPH) has 
shown a progressive increase, owing much to an increase 
in the elderly population, advancement in diagnostic meth-
ods, economic growth, and desire for a better quality of life. 
Ninety percent of men aged 85 or older are believed to have 
BPH [1], of whom 25% to 30% need therapy [2]. Treatment 
of lower urinary tract symptoms (LUTS) caused by BPH 
has advanced over the years, and numerous treatment op-
tions are now available. Most BPH can be treated effec-
tively with endoscopic surgery, with the exception of a large 
prostate volume, exceeding 100 g; until now, transurethral 
resection of prostate (TURP) has been the standard treat-Korean J Urol 2011;52:260-264
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TABLE 1. Characteristics of the patients 
Mean±SD Range
Age (yr) 71.1±7.7 52-94
IPSS-sum 18.4±8.5
   0-35
IPSS-voiding 11.5±5.1
   0-20
IPSS-storage
   7.6±3.9
   0-15
QoL score
   4.1±1.0 1-6
Qmax
   9.9±5.5
   1.5-25.0
PVR 89.6±207.1
      0-400
BOOI
   2.4±1.3 1-5
PSA
   3.8±2.7 0.2-7.5
Prostate volume 43.9±20.6
   14.8-119.8
IPSS: International Prostate Symptom Score, QoL: quality of life,
Qmax: maximum urinary flow rate, PVR: postvoid residual vol-
ume, BOOI: bladder outlet obstruction index, PSA: prostate-spe-
cific antigen
TABLE 2. Perioperative outcomes
Mean±SD Range
Operation time (min)   21.8±11.3 1-70
Applied energy (J) 170,068±63,181 2,886-2,750,415
Catheterization time (d) 1.01±0.2 1-3
ment of choice [3,4]. However, complications such as post-
operative bleeding, urethral stricture, urinary incontinence, 
retrograde ejaculation, and transurethral resection syn-
drome (TUR syndrome) have been reported at a high rate 
after TURP [5-7]. For this reason, numerous less-invasive 
alternative laser therapies have been proposed. However, 
most methods were not as effective as TURP and complica-
tion rates were unacceptably high [8].
　The 60 W potassium-titanyl-phosphate (KTP) laser pho-
toselective vaporization prostatectomy (PVP) was intro-
duced in the late 1990s, and the high powered 80 W KTP 
laser followed in the year 2000. This laser differs from the 
others in that it has a high absorption affinity for hemoglo-
bin and a low absorption affinity for water. The efficacy and 
safety of the laser are similar to those of traditional TURP, 
making it an ideal substitute for vaporization of prostate 
tissue [3,9-11].
　Recently, introduction of the 120 W lithium triborate 
(LBO) or the Greenlight high performance system (HPS) 
laser (American Medical Systems, Minnetonka, MN, 
USA), for which PVP efficacy and safety have been proven 
by many studies, was greeted with much applause [12,13]. 
The purpose of this study was to report on the long-term 
outcome of Greenlight HPS laser PVP in BPH patients on 
the basis of experience from a single institute.
MATERIALS AND METHODS 
1. Study population
From March 2009 to November 2010, 104 patients with 
symptoms consistent with LUTS were treated with 
Greenlight HPS (American Medical Systems, Minnetonka, 
MI, USA) laser PVP in our center. Inclusion criteria were 
symptoms that persisted after appropriate medical ther-
apy, refusal of proper medication due to side effects, ob-
struction on urodynamic studies, hematuria originating 
from the prostate, bladder stones, and persistent urinary 
tract infections. All patients were followed up for more than 
12 months after surgery. All patients were assessed with 
a complete medical history, physical examination, Inter-
national Prostate Symptom Score (IPSS), maximum uri-
nary flow rate (Qmax), postvoid residual volume (PVR), 
transrectal ultrasonography (TRUS), prostate-specific an-
tigen (PSA), complete blood cell count including hemoglo-
bin, urine analysis, and urodynamic study. Those with a 
palpable nodule, with a PSA value greater than 4 ng/ml, 
with a suspicious hypoechoic lesion in TRUS findings, who 
underwent concomitant transrectal prostate needle biop-
sy, and with pathology-proven prostate cancer were omit-
ted from our study.
2. Methods
General or spinal anesthesia was used, and surgery was 
performed by a single surgeon. A continuous running irri-
gation system 22 Fr resectoscope with a 30
o lens and a 75
o 
laser fiber was used. For continuous irrigation for a better 
surgical view, 0.9% normal saline was used. The 120 W 
HPS laser system (GreenLight, Laserscope
Ⓡ) was used, 
and vaporization was maintained at a distance of 1 mm 
from the prostate tissue for an optimal vaporization effect. 
Vaporization was started at the bladder neck in a clockwise 
manner, pulling the resectoscope further out and rotating 
the laser fiber simultaneously with power set at 60-120 W. 
Power was set at 30 W for coagulation. All prostate tissue 
causing obstruction was removed until a fine surgical cav-
ity was formed, as in TURP. An 18 Fr urethral catheter was 
placed after the operation and it was removed the next day, 
taking into consideration the degree of hematuria.
3. Assessment
Postoperative Qmax, PVR, and IPSS with QoL score were 
obtained at 1, 3, 6, and 12 months after surgery. Operation 
time, applied energy, and duration of catheterization were 
obtained. Postoperative Qmax, PVR, IPSS, and QoL score 
were compared with preoperative values by using the 
Wilcoxon signed-rank test; p-values of less than 0.05 were 
defined as statistically significant. 
RESULTS
A total of 104 patients met the inclusion criteria. The pa-
tients’ mean age was 71.1 years, and the mean follow-up 
period was 15.2 months (range, 12-18 months). Preopera-
tive parameters were as follows: IPSS: 18.4±8.5, QoL: 
4.1±1.0, Qmax: 9.9±5.5 ml/s, PVR: 89.6±207.1 ml, PSA: 
3.8±2.7 ng/ml, and prostate volume: 43.9±20.6 g (Table 1). 
Mean operation time was 21.8±11.3 minutes, mean lasing 
time was 16.9±10.5 minutes, and mean applied energy was Korean J Urol 2011;52:260-264
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FIG. 1. Changes in preoperative and postoperative IPSS scores.
IPSS: International Prostate Symptom Score, Preop: preopera-
tive characteristics, PVP: photoselective vaporization of prostate,
QoL: quality of life, 
a: p＜0.05 compared with preoperative IPSS
scores.
FIG. 2. (A) Preoperative and postoperative values of Qmax. (B) Preoperative and postoperative PVR. Qmax: maximum urinary flow
rate, PVR: postvoid residual volume, Preop: preoperative, Postop: postoperative.
170,068±63,181 J. Mean catheterization duration was 
1.01±0.2 days (Table 2). One month after surgery, subjective 
and objective follow-up parameters were assessed and sta-
tistical analysis was performed. Compared with the pre-
operative data, statistically significant improvements were 
observed in total IPSS (11.5±6.7, p＜0.05), the voiding 
symptom score (6.1±5.4, p＜0.05), and the QoL score (2.2± 
1.5, p＜0.05); however, there were no statistically signi-
ficant improvements in the storage symptom score (4.8±3.8, 
p=0.06), Qmax (12.6±10.2, p=0.06), and PVR (40.1±30.5, 
p=0.41). Three months after the operation, all parameters 
were reassessed, and the statistical analysis was per-
formed again. Compared with the preoperative data, sig-
nificant improvements were observed in total IPSS (9.4± 
7.1, p＜0.05), the voiding symptom score (5.7±4.5, p＜0.05), 
the storage symptom score (3.9±3.8, p＜0.05), the QoL score 
(1.8±1.2, p＜0.05), Qmax (13.3±8.7, p＜0.05), and PVR 
(32.9±34.6, p＜0.05). All postoperative follow-up parame-
ters were assessed again at 6 and 12 months after surgery. 
The 6-month total IPSS was 6.9±1.5, the voiding symptom 
score was 3.1±2.7, the storage symptom score was 3.8±2.2, 
the QoL score was 1.7±1.5, Qmax was 14.4±7.3 ml/s, and 
PVR was 29.3±28.9 ml. The 12-month total IPSS was 
5.0±6.1, the voiding symptom score was 2.5±4.4, the storage 
symptom score was 2.5±2.4, the QoL score was 1.0±0.8, 
Qmax was 19.9±7.5 ml/s, and PVR was 13.7±1.2 ml. All of 
the above 3, 6, and 12-month postoperative values were 
statistically significant when compared with baseline val-
ues and were sustained throughout the follow-up period 
(Fig. 1, 2). The only major postoperative complication in our 
study was mild dysuria (n=14, 13.4%), which improved 
with conservative care. There were no complications such 
as delayed hematuria or obstructive retention with blood 
clot. 
DISCUSSION
The prevalence of BPH has shown a progressive increase, 
owing much to an increase in the elderly population, ad-
vancement in diagnostic methods, economic growth, and 
desire for a better quality of life. Ninety percent of men aged 
85 or older are believed to have BPH [1], of whom 25% to 
30% need therapy [2].
　Despite the large number of alternative procedures 
available, TURP remains the gold standard surgical tech-
nique for experienced surgeons. However, with the recent 
increase of interest in nonsurgical methods and minimally 
invasive therapy, many laser-using techniques for the 
treatment of BPH have been developed.
　The neodymium:yttrium-aluminum-garnet (Nd:YAG) 
laser generates a frequency of 1,064 nm and is not selectively 
absorbed by prostate tissue. The Nd:YAG laser energy is 
mainly converted into heat and causes a deep coagulation 
zone. The major disadvantage of the Nd:YAG laser is the 
requirement for prolonged bladder drainage, longer hospi-
talization, poor maintenance of initial symptom improve-Korean J Urol 2011;52:260-264
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ments, and higher rates of reoperation [14]. 
    In 1998, Malek et al introduced the KTP laser. The photo-
selectivity of the green 532 nm laser wavelength is based 
on the fact that this visible wavelength is strongly absorbed 
within the very superficial layer of tissue [15]. The KTP la-
ser emits visible green light at a wavelength of 532 nm, 
which is strongly absorbed by oxyhemoglobin, but hardly 
at all by water, which prevents the beam from penetrating 
into deeper tissue layers. The heat generated by absorption 
of the KTP laser energy leads to the formation of vapor bub-
bles inside the targeted tissue. Continued exposure of the 
targeted area to KTP laser energy leads to progressive va-
porization of the newly exposed deeper layers of tissue. 
Tissue ablation is visible in real time by the continuous re-
lease of bubbles from the tissue surface during the laser 
procedure. Therefore, the KTP laser can immediately re-
move obstructive prostatic adenoma without bleeding or 
deep tissue necrosis. Many recent studies have reported 
that values for IPSS, Qmax, and QoL after the KTP laser 
are equivalent to those after TURP [8,10,11,16]. In addi-
tion, the safety of patients taking anticoagulants has been 
confirmed [17,18].
    On the other hand, the primary disadvantage of the 80 
W KTP laser is that the vaporizing power of the tissue is 
very low, which lengthens the operation time. To overcome 
this shortcoming, the 120 W HPS laser was introduced in 
2006.
　When the 80 W KTP laser is used, the operation time for 
treatment of BPH shows a wide range [16,19]. According 
to one domestic report, the mean lasing time was 44.9 min; 
however, our mean lasing time in the present study was 
21.8 min [20]. We were able to conclude that use of the 120 
W HPS laser resulted in a shortened operation time.
    Bouchier-Hayes reported that in a trial of 80 W laser PVP 
with 120 patients, IPSS showed a decrease from a pre-
operative value of 25.3 to 8.9 after 12 months and Qmax in-
creased from 8.8 ml/s to 18.6 ml/s [16]. In the present study 
with 120 W HPS laser PVP, IPSS changed from a preopera-
tive value of 18.4 to 11.5, 9.4, 6.9, and 5.0 at 1, 3, 6, and 12 
months after surgery, respectively; and Qmax changed 
from 9.9 ml/s preoperatively to 12.6, 13.3, 14.4, and 19.9 
ml/s after 1, 3, 6, and 12 months, respectively. Compared 
with the reported results for the use of the 120 W HPS laser 
by Al-Ansari et al, Son et al and Ko et al, the decrease in 
IPSS and increase in Qmax were similar in this study [21- 
23].
    Spaliviero et al reported postoperative complications of 
70% for nonspecific hematuria, which disappeared within 
1 week, and of 14.3% for retrograde ejaculation after 120 
W HPS laser PVP [13]. Retrograde ejaculation rates of 70% 
to 100% after TURP and of 96% after HoLEP have been re-
ported [24]. On the basis of this report, 120 W HPS laser 
PVP has a low incidence of sexual dysfunction by retro-
grade ejaculation; therefore, we can recommend that this 
procedure can be performed safely in patients who wish to 
maintain their sexual ability.
    In general, in cases of preoperative urethral catheter-
ization due to urinary retention, intake of anticoagulant 
medication and a large prostate show low satisfaction with 
increased complication rates after the operation. One 
ex-vivo report on the 120 W HPS laser showed a higher 
hemorrhagic rate compared with the 80 W HPS laser [25]. 
However, in research recently reported by the interna-
tional Greenlight laser user group, in cases in which the 
size of the prostate was over 80 g, IPSS decreased from a 
preoperative value of 22.1 to a postoperative value of 8, 
Qmax increased from 5.8 to 19.7, and PVR decreased from 
118.4 to 55.5. In that study, data were collected from 65 uri-
nary retention patients, 70 patients on anticoagulants, and 
52 patients with BPH over 80 g, and IPSS, Qmax, and PVR 
were noted pre- and postoperatively. Other satisfactory re-
sults have also been reported [26].
    The results of these reports suggest that the 120 W HPS 
laser can be applied safely to patients with a history of uri-
nary retention, to patients taking anticoagulant medi-
cation, and in patients with a large prostate over 80 g.
　In our study, IPSS decreased from a preoperative value 
of 24.0 to a postoperative value of 6.2, Qmax increased from 
6.69 to 10.64, and PVR decreased from 102.5 to 35.7 in 11 
patients with a prostate size over 80 g.
    The interesting result of our study was that some post-
operative follow-up parameters showed no significant im-
provement at 1 month after the operation; however, 3 
months later, all parameters showed significant improve-
ment. We think that this result was due to postoperative 
tissue edema or bladder irritative symptoms remaining up 
to 1 month after the operation. Therefore, we recommend 
observation of symptomatic improvements for at least 1 
month after surgery.
    Among the participants of our study, two patients under-
went the operation because their satisfaction with uri-
nation was low and they strongly wanted the operation, al-
though we did not advise the operation because their Qmax 
was high. After the operation, however, there was a sig-
nificant improvement in IPSS and QoL and patient sat-
isfaction was high for all of them.
CONCLUSIONS
Interest in nonsurgical methods and minimally invasive 
therapy has shown a recent increase, and many techniques 
using lasers for the treatment of BPH have been developed. 
We conducted an analysis of the long-term postoperative 
effects of 120 W HPS laser PVP procedures and confirmed 
improved, or at least the same, results compared with 
TURP procedures or the conventional KTP laser. Our expe-
riences suggest that the 120 W HPS laser PVP procedure 
is safe and effective. A longer period of data observation of 
a larger population and postoperative complications 
should be evaluated next.
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